Screener Summaries Updates Institutions Sign In More Updates › Other Events › CPRX Other Events · Jun 30, 2026
On June 30, 2026, Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 clinical study of AGAMREE… CPRX Catalyst Pharmaceuticals, Inc.
On June 30, 2026, Catalyst Pharmaceuticals announced topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone). The company operates in the pharmaceutical industry and develops treatments for rare diseases.
More from Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. completed its merger with Angelini Pharma S.p.A. on July 15, 2026, becoming a wholly… Jul 15, 2026 Catalyst Pharmaceuticals, Inc. stockholders at a special meeting held on July 8, 2026, approved the merger proposal to… Jul 8, 2026 Catalyst Pharmaceuticals, Inc. announced that the FTC granted early termination of the HSR Act waiting period for its… Jun 23, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
